<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: We have recently demonstrated that pretreatment with <z:chebi fb="131" ids="25107">magnesium</z:chebi> (calcium and <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> <z:chebi fb="68" ids="48706">antagonist</z:chebi>) and tirilazad (<z:chebi fb="11" ids="22586">antioxidant</z:chebi>) in combination with intraischemic mild <z:hpo ids='HP_0002045'>hypothermia</z:hpo> (33 degrees C) (MTH) offers superior neuroprotective efficacy in a rat model of focal transient <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In the present study, we investigated the time window of this treatment strategy with a posttreatment regimen to define its role for <z:hpo ids='HP_0001297'>stroke</z:hpo> patients </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We subjected 48 Sprague-Dawley rats to 90 minutes of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> by an intraluminal filament </plain></SENT>
<SENT sid="3" pm="."><plain>Bilateral regional cerebral blood flow was continuously recorded by laser Doppler flowmetry </plain></SENT>
<SENT sid="4" pm="."><plain>Combination therapy with MTH was started at 0, 1, 3, and 5 hours after induction of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Drugs were given in 1-hour intervals, and <z:hpo ids='HP_0002045'>hypothermia</z:hpo> was maintained for 2 hours </plain></SENT>
<SENT sid="6" pm="."><plain>Neurological deficits were assessed daily </plain></SENT>
<SENT sid="7" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> size was planimetrically determined on postoperative day 7 </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: Combination therapy with MTH significantly reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume compared with normothermic controls by -74%, -49%, and -45% when applied at 0, 1, and 3 hours after induction of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Furthermore, these treatment groups showed less neurological deficits on postischemic days 1 and 2 (P&lt;0.05) </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0003674'>Onset</z:hpo> of treatment 5 hours after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> failed to significantly reduce <z:mpath ids='MPATH_124'>infarct</z:mpath> formation and neurological deficits </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: The therapeutic window of the new combination therapy is at least 3 hours after <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, comparable to that of moderate <z:hpo ids='HP_0002045'>hypothermia</z:hpo> (30 degrees C), a grade of <z:hpo ids='HP_0002045'>hypothermia</z:hpo> associated with higher risks of severe side effects </plain></SENT>
</text></document>